Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment

Daniel Orive Mauleón; Mirari Echepare Taberna; Franco Bernasconi Bisio; Miguel Fernández de Sanmamed Gutierrez; Antonio Pineda Lucena; Carlos de la Calle Arroyo; Frank Detterbeck; Rayjean J. Hung; Mattias Johansson; Hilary A. Robbins; Luis Miguel Seijo Maceiras; Luis Montuenga Badía; Karmele Valencia Leoz

Ayuda

Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment

Daniel Orive ^[3] ; Mirari Echepare ^[3] ; Franco Bernasconi Bisio ^[4] ; Miguel Fernández Sanmamed ^[5] ; Antonio Pineda Lucena ^[6] ; Carlos de la Calle Arroyo ^[1] ; Frank Detterbeck ^[2] ; Rayjean J. Hung ^[7] ; Mattias Johansson ^[8] ; Hilary A. Robbins ^[8] ; Luis M. Seijo ^[9] ; Luis M. Montuenga ^[3] ; Karmele Valencia ^[3]
1. [1] Universidad de Navarra
  
  Universidad de Navarra
  
  Pamplona, España
2. [2] Yale School of Medicine
  
  Yale School of Medicine
  
  Town of New Haven, Estados Unidos
3. [3] Solid Tumors Program, CIMA-University of Navarra, Pamplona, Spain
4. [4] Molecular Therapeutics Program, CIMA-University of Navarra, Pamplona, Spain
5. [5] Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
6. [6] Navarra Health Research Institute (IDISNA), Pamplona, Spain
7. [7] Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada
8. [8] International Agency for Research on Cancer, Lyon, France
9. [9] CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain
Mostrar afiliaciones +
Localización: Archivos de bronconeumología: Organo oficial de la Sociedad Española de Neumología y Cirugía Torácica SEPAR y la Asociación Latinoamericana de Tórax ( ALAT ), ISSN 0300-2896, Vol. 60, Nº. Extra 2, 2024 (Ejemplar dedicado a: Lung cancer: New perspectives), págs. 67-76
Idioma: inglés
Enlaces
- Texto completo
Resumen
- Lung cancer remains the leading cause of cancer-related deaths worldwide, mainly due to late diagnosis and the presence of metastases. Several countries around the world have adopted nation-wide LDCT-based lung cancer screening that will benefit patients, shifting the stage at diagnosis to earlier stages with more therapeutic options. Biomarkers can help to optimize the screening process, as well as refine the TNM stratification of lung cancer patients, providing information regarding prognostics and recommending management strategies. Moreover, novel adjuvant strategies will clearly benefit from previous knowledge of the potential aggressiveness and biological traits of a given early-stage surgically resected tumor. This review focuses on proteins as promising biomarkers in the context of lung cancer screening. Despite great efforts, there are still no successful examples of biomarkers in lung cancer that have reached the clinics to be used in early detection and early management. Thus, the field of biomarkers in early lung cancer remains an evident unmet need.
  
  A more specific objective of this review is to present an up-to-date technical assessment of the potential use of protein biomarkers in early lung cancer detection and management. We provide an overview regarding the benefits, challenges, pitfalls and constraints in the development process of protein-based biomarkers. Additionally, we examine how a number of emerging protein analytical technologies may contribute to the optimization of novel robust biomarkers for screening and effective management of lung cancer.